Drug Profile
Talquetamab - Genmab/Janssen Research & Development
Alternative Names: GPRC5D/CD3-duobody-antibody-JNJ-64407564; JNJ 64407564; JNJ-7564; TALVEYLatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 04 Apr 2024 University of California and Janssen Research & Development plans a phase Ib trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT06348108)
- 29 Jan 2024 Janssen Research & Development initiates the phase III MonumenTAL-6 trial in Multiple myeloma (Combination therapy) in Australia and South Korea (SC) (NCT06208150)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Canada (SC, Injection)